Portfolio company
CND Life Sciences
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops skin biopsy tests to detect alpha-synuclein pathology for clinicians and biopharmaceutical researchers diagnosing neurodegenerative diseases like Parkinson's.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Neurovision
This company provides diagnostic blood tests and retinal imaging software to help healthcare providers detect and monitor neurodegenerative diseases.
Insignals Neurotech
This company develops wearable devices and software for Parkinson's disease monitoring and symptom assessment for clinicians, researchers and patients.
Cytox
This company develops non-invasive genetic tests for Alzheimer's disease risk assessment and patient stratification for clinicians and pharmaceutical researchers.
Pre Diagnostics
This company develops intracellular blood tests and biomarker analytical services for the early detection of Alzheimer's disease for patients, practitioners and researchers.
Circular Genomics
This company develops circular RNA blood tests for diagnosing neurological and psychiatric disorders for healthcare providers, researchers and pharmaceutical organisations.
Alzeca Biosciences
This company develops MRI contrast agents to enable early diagnosis of Alzheimer's disease and other neurodegenerative disorders for healthcare providers and clinical researchers.
GLX Analytix
This company develops blood-based diagnostic and monitoring tests for clinicians to manage neurodegenerative, autoimmune and neuropsychiatric diseases using glycocalyx biomarkers and artificial intelligence.
Cleveland Diagnostics
This company develops blood-based protein biomarker tests for early cancer detection to help clinicians and laboratories identify high-risk patients and reduce unnecessary biopsies.
